scholarly journals A Case Series of Two Patients Presenting With Pericardial Effusion as First Manifestation of Non-Small Cell Lung Cancer With BRAF Mutation and Expression Of PD-L1

2018 ◽  
Vol 9 (2) ◽  
pp. 56-61
Author(s):  
Muhammad Mufti ◽  
Steven Ching ◽  
Sassan Farjami ◽  
Sharareh Shahangian ◽  
Serap Sobnosky
Keyword(s):  
Lung Cancer ◽  
Pericardial Effusion ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Braf Mutation ◽  
Case Series ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Treatment Response To Osimertinib In EGFR-Mutated Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Series

2019 ◽  
Vol Volume 12 ◽  
pp. 7785-7790 ◽  
Author(s):  
Huiying Li ◽  
Tingting Yu ◽  
Mingmin Huang ◽  
Aibin Guo ◽  
Xiaoping Qian ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Treatment Response ◽  
Cell Lung Cancer ◽  
Case Series ◽  
Small Cell ◽  
Leptomeningeal Metastases ◽  
Small Cell Lung

scholarly journals Systemic Chemotherapy for Progression of Brain Metastases in Extensive-Stage Small Cell Lung Cancer

2015 ◽  
Vol 2015 ◽  
pp. 1-3 ◽  
Author(s):  
Nagla Abdel Karim ◽  
Ananta Bhatt ◽  
Lauren Chiec ◽  
Richard Curry
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Systemic Chemotherapy ◽  
Case Series ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancers ◽  
Lung Cancer Patients

Lung cancer is the most common cause of cancer related mortality in men and women. Approximately 15% of lung cancers are small cell type. Chemotherapy and radiation are the mainstay treatments. Currently, the standard chemotherapy regimen includes platinum/etoposide. For extensive small cell lung cancer, irinotecan and cisplatin have also been used. Patients with relapsed small cell lung cancer have a very poor prognosis, and the morbidity increases with brain metastases. Approximately 10%–14% of small cell lung cancer patients exhibit brain metastases at the time of diagnosis, which increases to 50%–80% as the disease progresses. Mean survival with brain metastases is reported to be less than six months, thus calling for improved regimens. Here we present a case series of patients treated with irinotecan for progressive brain metastases in small cell lung cancer, which serves as a reminder of the role of systemic chemotherapy in this setting.

Sign in / Sign up

Export Citation Format

Share Document